Braveheart Bio, Inc.

Braveheart Bio, Inc. , based in the US, is dedicated to developing innovative therapies targeting hypertrophic cardiomyopathy (HCM), focusing on enhancing heart function through advanced clinical treatments. Braveheart Bio, Inc. is focused on creating therapies for hypertrophic cardiomyopathy (HCM).

The company is headquartered in San Francisco, US. In November 2025, it raised USD 185. 00 mn in Series A funding from notable investors including Andreessen Horowitz and Forbion. The founder's history is not specified.

As of November 2025, Travis Murdoch is the Chief Executive Officer (CEO) of the company. Braveheart Bio is engaged in advancing treatments for hypertrophic cardiomyopathy (HCM) through investigational therapies that target overactive myosin. These therapies aim to improve heart performance by counteracting excessive force during contractions, which causes abnormal thickening of the heart muscle, primarily in the left ventricle. Currently, these products are in late-stage clinical development to enhance patient outcomes for the approximately 1 in 500 individuals affected by HCM in the US and globally, with potential expansion into international markets such as Europe and Asia.

Braveheart's revenue model centers on partnerships and collaborations within the biopharmaceutical sector, focusing on delivering novel therapies to healthcare providers and institutions. Revenue is generated through licensing agreements and collaborations with pharmaceutical companies, facilitating distribution and access to investigational treatments. The business structure prioritizes relationships with healthcare systems and engagement with clinical trial networks, ensuring effective distribution upon regulatory approval. Pricing strategies for the therapies are negotiated based on therapeutic value and prevailing market conditions, adhering to industry standards for advanced biopharmaceutical products.

Braveheart plans to leverage its recent Series A funding of USD 185. 00 mn, raised in November 2025, to support the launch of its investigational therapies targeting hypertrophic cardiomyopathy (HCM). The company aims to expand its market presence into Europe and Asia by 2026, addressing the global need for effective HCM treatments. The investments will be directed toward further clinical development and regulatory approval processes to enhance access to their innovative therapies.